key: cord-0741946-r82vkg5x
authors: Padmapriyadarsini, C.; Banurekha; Arora, V.K.
title: Challenges in TB Control and the Anticipated COVID-19 Third Wave: Way Forward
date: 2021-07-28
journal: Indian J Tuberc
DOI: 10.1016/j.ijtb.2021.07.014
sha: d83afd61f434694de7c6263d64f3628cfa24cb3a
doc_id: 741946
cord_uid: r82vkg5x

nan

At the time of writing this, Coronavirus disease 2019 (COVID-19) continues to remain a major global issue. The second wave of COVID-19 between April 2021 -June 2021 has severely affected the Indian subcontinent. As countries succeed in overcoming the COVID-19 second wave to an extent with vaccines and drugs, the fear of an impending third wave looms large. In nations like Africa, Brazil, India and Southeast Asia, the COVID-19 crisis may converge with another common infectious disease: tuberculosis (TB) [1, 2] . TB and COVID-19 are currently the two main causes of death due to infectious diseases. The convergence between these two diseases raises concerns among health authorities, especially in TB endemic countries -Is COVID-19 flaring up TB? What will be the impact of the impending third wave on TB control? Can it be minimized?

Effect of COVID-19 on TB Management: Worldwide this viral pandemic has caused a setback to the gains achieved in TB control by impairing TB diagnosis, delaying treatment initiation, aggravating TB deaths which in turn will adversely impact the TB Elimination targets of 2030. Since both TB and COVID-19 primarily affect the lungs, they share common symptoms which include cough, fever and breathing difficulty. Persistent respiratory symptoms in post-COVID-19 recovered patients can be mistaken as COVID-19 sequelae or secondary infection and delay the diagnosis of TB. When patients with such symptoms are hospitalized, in the background of the pandemic, the patches or opacities seen on chest x-ray and CT scan are assumed to be due to COVID-19, and the diagnosis of TB is missed which flares up later during post-COVID recovery. The delay in diagnosis of TB can result in increased severity of the disease at presentation as well as the risk of TB transmission in the community. Also, during this period the GeneXpert machines were diverted for COVID-19 testing instead of testing for TB. Further, those hospitalized for COVID-19 were administered high doses of corticosteroids whether or not clinically indicated. Once initiated on TB treatment, adherence and continuation of treatment were also impacted by the pandemic. Supply and supervision of TB drug administration were severely affected due to the mobilization of TB program staff to tackle the COVID-19 pandemic.

Transportation of drugs and medical supplies, as well as restricted mobility of patients and healthcare staff due to multiple lockdowns, resulted in a delay in TB diagnosis, treatment initiation and follow-up leading to missed doses and treatment failure. Even BCG vaccination of children was severely reduced during this pandemic [3] . Another important aspect is that both TB and COVID-19 share similar social determinants, including overcrowding, poverty, and air pollution [4] . Extended lockdown periods resulted in lack of jobs affecting the family economy severely. Hence with the lifting of lockdown, people are more eager to return to jobs and livelihood rather than seek health care thus further delaying the diagnosis.

Increasing COVID-19 cases took a heavy toll on the health care system. Many staff in other national programs including the TB Elimination program were diverted to work in COVID care centers. Redeployment of TB services staff and reallocation of finances to COVID-related activities has impacted all activities of the TB elimination program from diagnosis to treatment and prevention. Supply chains were disrupted in many parts of the country. TB notification decreased between January 2020 -June 2020 [5] . All this will adversely affect our progress made towards TB elimination targets. Global TB report 2020 has recognized this threat of COVID-19 and has called for action to accelerate progress towards global TB targets [5] .

Preparing for the "next": India has faced two waves of COVID-19 so far -first in November -December 2020 and the second in March -April 2021. Given the emergence of new viral variants with higher transmissibility, lifting of lockdown, waning of protective immunity against the virus amongst the vaccines, there is a probability of a third wave of COVID-19maybe of a milder nature [6] . Also, the intervening period between the COVID-19 waves is when we have to be cautious. Surveillance for both TB and COVID-19 needs to be meticulously followed as there is every likelihood that respiratory symptoms may be mistaken for one or the other. Also, an increase in TB cases may be expected in the post-COVID phase. This could be due to the combination of relaxation of lockdown with the availability of better transportation facilities, return of TB staff on CoV2 duty to their respective diagnostic centers leading to more TB cases being diagnosed. Activation of latent TB during the post-COVID phase can further worsen the situation. Hence, these individuals may need close monitoring for an extended period of time.

With the emergence of newer CoV2 variants like delta-plus and lambda, their effect on TB disease and latent TB infection have to be closely monitored. Continuous surveillance of both diseases is the need of the hour. There is not sufficient evidence available to suggest that the COVID-19 third wave will largely affect children. Research so far has indicated that healthy children have milder disease, better prognosis and low mortality in comparison to adults. Hence, when we commence vaccination in children, and scale-up for other age groups, those with a higher risk must get vaccinated first followed by the group at lesser risk. To summarize, this pandemic revealed that newer diagnostics, treatment, and vaccines can be rapidly developed, fast-tracked for regulatory approvals and made available for patient management when they are fully supported politically and financially with public-private and industry-academic partnerships. 

The potential impact of COVID-19-related disruption on tuberculosis burden

COVID-19, tuberculosis, and poverty: preventing a perfect storm

India's syndemic of tuberculosis and COVID-19

Severe acute respiratory syndrome coronavirus-2 and pulmonary tuberculosis: convergence can be fatal. Monaldi Arch Chest Dis

Geneva: World Health Organization

Plausibility of a third wave of COVID-19 in India: A mathematical modelling based analysis

Stop TB Partnership in collaboration with Imperial College. The Potential impact of the COVID-19 response on Tuberculosis in High burden countries. A modelling analysis